Fig. 5: Treatment with rmFGF21 relieved I/R-induced hepatocellular injury.

a Experimental schema for establishing the I/R injury mouse model. The mice were intravenously administered rmFGF21 (0.5 mg/kg). b Serum ALT and AST levels 6 h after reperfusion (n = 5, per group). c Comparison of serum FGF21 levels 6 h after reperfusion (n = 5, per group). d H&E staining of liver sections 6 h after reperfusion (n = 5, per group). e Western blot analysis (left) and quantification (right) of FGF21and BAX in AML12 from each group. f Western blot analysis (left) and quantification (right) of ALOX15, BAX and p-ERK1/2 in AML12 from each group. g Western blot analysis (up) and quantification (down) of ALOX15, BAX and p-FGFR4 in AML12 from each group. e–g three independent biological mice samples. I/R ischemia/reperfusion, ALT alanine aminotransferase, AST aspartate aminotransferase, H/R hypoxia/ reoxygenation. Two-tailed t-test. Statistic data are presented as the mean ± SD, error bars represent the means of at least three independent experiments. p values are shown on the graphs, p < 0.05 was considered statistically significant. Source data are provided as a Source Data file. Figure 5a created with BioRender. com released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license (https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en).